Eight years with haemovigilance in Norway. What have we learnt?

Transfusion and Apheresis Science

Volumn 49, Issue 3, 2013, Pages 548-552

  Steinsvåg, Christine Torsvik ^a,b   Espinosa, Aurora ^a,c   Flesland, Øystein ^a,d  

^a NORWEGIAN KNOWLEDGE CENTRE FOR THE HEALTH SERVICES   (Norway)

^b Sørlandet Hospital Health Enterprise   (Norway)

^c TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^d Vestre Viken HF ^*  (Norway)

Author keywords

Adverse reaction; Haemovigilance; Transfusion

Indexed keywords

OCTAPLAS; THROMBOCYTE CONCENTRATE;

ANAPHYLAXIS; APHERESIS; ARTICLE; AUTOIMMUNE HEMOLYTIC ANEMIA; BACTERIAL TRANSMISSION; BLOOD COMPONENT; BLOOD SAFETY; DYSPNEA; ERYTHROCYTE CONCENTRATE; ERYTHROCYTE TRANSFUSION; HEPATITIS A VIRUS; HEPATITIS C VIRUS; HUMAN; HUMAN PARVOVIRUS B19; HYPERKALEMIA; MORTALITY; NORWAY; PURPURA; THROMBOCYTE TRANSFUSION; TRANSFUSION ASSOCIATED GRAFT VERSUS HOST DISEASE; TRANSFUSION RELATED ACUTE LUNG INJURY; VARICELLA ZOSTER VIRUS; VASCULITIS; VIRUS TRANSMISSION;

ADVERSE REACTION; HAEMOVIGILANCE; TRANSFUSION;

BLOOD BANKS; BLOOD DONORS; BLOOD SAFETY; BLOOD TRANSFUSION; HUMANS; NORWAY;

EID: 84888432559     PISSN: 14730502     EISSN: 18781683     Source Type: Journal    
DOI: 10.1016/j.transci.2013.09.013     Document Type: Article

References (15)

1. [08.09.13]. http://www.ansm.sante.fr/Mediatheque/Publications/Information-in-English.
2. Taylor C, et al. editors. On behalf of the Serious Hazards of Transfusion (SHOT) Steering Group. The 2009 Annual SHOT Report, 2010. [08.09.13]. http://www.shotuk.org/shot-reports/report-and-summary-2009/.
3. Flesland Ø, Bergan TO. Blodtransfusjonstjenesten i Norge. Statistikk for 2004-2007. NFIT. < and > [08.09.13]. http://www.hemovigilans.no.
4. Flesland Ø, Sjøberg JJ. Blodtransfusjonstjenesten i Norge. Statistikk for 2008-2011. Blodbanken, Bærum sykehus, VVHF. [08.09.13]. http://www.hemovigilans.no.
5. Directive 2002/98/EC of the European Parliament and of the Council of 27 January 2003 [08.09.13]. http://www.eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2003:033:0030:0040:EN:PDF.
6. [08.09.13]. http://www.hemovigilans.no.
7. Stene-Johansen K., et al. Hepatitt A-smitte ved transfusjon. Tidsskr Nor Legeforen 2010, 130:1020-1021.
8. Veileder for transfusjonstjenesten i Norge. Helsedirektoratet. 6.utg. 2009. [08.09.13]. http://www.helsedirektoratet.no/publikasjoner/veileder-for-transfusjonstjenesten-i-norge-6-utgave-2009/Sider/default.aspx.
9. TRIP annual report 2009 Hemovigilance. [08.09.13]. http://www.tripnet.nl/pages/en/publicaties.php.
10. Espinosa A., Brobakk G.M., et al. Improving transfusion safety by implementation of a certification program for doctors and nurses. Blood Transfus 2011, 9(Suppl. 1). V01:38.
11. Chapman C., et al. Ten years of haemovigilance reports of transfusion related acute lung injury in the UK and the impact of preferential use of male donor plasma on behalf of the Serious Hazards of Transfusion (SHOT) steering group. Transfusion 2009, 49:440-452.
12. Williamson L.M., et al. The impact of universal leukodepletion of the blood supply on hemovigilance reports of posttransfusion purpura and transfusion-associated graft-versus-host disease. Transfusion 2007, 33:1456-1467.
13. Steinsvåg TT, et al. Troll. The haemovigilance annual report on blood transfusion and donation in Norway 2004 by the Haemovigilance working group of The Norwegian Association of Immunology and, Transfusion Medicine. [08.09.13]. http://www.hemovigilans.no.
14. Flesland O. A comparison of complication rates based on published haemovigilance data. Intensive Care Med 2007, 33(Suppl 1):S17-S21.
15. White JL. Adverse event reporting and learning systems: a review of the relevant literature. The Canadian Patient safety Institute (CPSI) 2007. [08.09.13]. http://www.gov.nl.ca/ahe/submissions/05_CanadianPatientSafetyInstitute.pdf.